Przemyslaw Sapieha - Unity Biotechnology Chief Scientist
| UBX Stock | USD 1.21 0.02 1.68% |
Executive
Przemyslaw Sapieha is Chief Scientist of Unity Biotechnology
| Address | 285 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 416 1192 |
| Web | https://unitybiotechnology.com |
Unity Biotechnology Management Efficiency
The company has Return on Asset of (0.3034) % which means that on every $100 spent on assets, it lost $0.3034. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8695) %, meaning that it generated no profit with money invested by stockholders. Unity Biotechnology's management efficiency ratios could be used to measure how well Unity Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.81 in 2024. At this time, Unity Biotechnology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 25.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 57.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caren Deardorf | Editas Medicine | 59 | |
| Michael MD | Exscientia Ltd ADR | 63 | |
| Toshiya DVM | Ovid Therapeutics | N/A | |
| Nikolaus Krall | Exscientia Ltd ADR | N/A | |
| MarieLouise MD | Exscientia Ltd ADR | 60 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Joan MBA | Verve Therapeutics | 55 | |
| Linda Burkly | Editas Medicine | 67 | |
| Lora Pike | Ovid Therapeutics | N/A | |
| Sara Sherman | Exscientia Ltd ADR | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Ryan Craig | Heron Therapeuti | N/A | |
| Keith Pietropaolo | Atea Pharmaceuticals | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Simon Kelner | Ovid Therapeutics | 50 | |
| Sourav Kundu | NextCure | 63 | |
| Udayan MD | NextCure | N/A | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
| David MD | Intellia Therapeutics | 69 | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| Janelle Gordon | Recursion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.3 |
Unity Biotechnology Leadership Team
Elected by the shareholders, the Unity Biotechnology's board of directors comprises two types of representatives: Unity Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Unity. The board's role is to monitor Unity Biotechnology's management team and ensure that shareholders' interests are well served. Unity Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Unity Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr AB, CoFounder Director | ||
| Nathan Guz, Vice Operations | ||
| Judith Campisi, Founder | ||
| Daohong MD, Founder | ||
| Anirvan Ghosh, CEO Director | ||
| Jamie MD, Chief Officer | ||
| Lynne CPA, CFO Development | ||
| Alexander Azoy, Chief Officer | ||
| Jan Deursen, Founder | ||
| Lynne Sullivan, CFO Development | ||
| Alicia MBA, Chief Officer | ||
| Przemyslaw Sapieha, Chief Scientist | ||
| Alexander JD, General Secretary | ||
| MPH MD, Head Officer |
Unity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Unity Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 11.71 M | ||||
| Shares Outstanding | 16.85 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 20.54 % | ||||
| Number Of Shares Shorted | 303.04 K | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 6.54 X | ||||
| Gross Profit | (35.22 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.